Earnings History Data for AbbVie Inc. (ABBV) - NYSE NASDAQ

To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.

For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.

See the full list of available companies here.

AbbVie Inc.

AbbVie is a global, research-based biopharmaceutical company. AbbVie combines the focus and passion of a leading-edge biotech with the expertise and structure of a long-established pharmaceutical leader. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. AbbVie aims to help patients' live healthier lives and collaborate on sustainable healthcare solutions.

Release Date	Time	Est. Time	Symbol	Name	Market Cap (M)	Rep. EPS	Est. EPS	Last years EPS	SeekingAlpha Headline	Price	Change	Ext. Hours Price	Ext. Hours Change	52 Week Range	Volume	Avg. Volume	Ext. Hours Volume
30-10-2024	PM		ABBV	AbbVie Inc.	335,040	3.00	2.92	2.95	AbbVie Non-GAAP EPS of $3.00 beats by $0.08, revenue of $14.46B beats by $180M [10/30/2024 7:40 AM]	201.68	12.23 (6.45%)	192.00	2.55 (1.35%)	135.85 - 202.35	7,540,378	5,090,000	330,202
AbbVie lifts dividend by 5.8% to $1.64/share [10/30/2024 7:48 AM] Earnings Snapshot: AbbVie FY profit guidance beats forecast, Q3 Humira revenue lags [10/30/2024 8:00 AM] AbbVie lifts outlook again on immunology demand; dividend raised [10/30/2024 8:10 AM] AbbVie in charts: Humira Q3 revenues of $2.23B plunges 37%, Skyrizi, Rinvoq gain Y/Y [10/30/2024 8:11 AM] What’s behind AbbVie's Q3 revenue beat? [10/30/2024 1:58 PM] AbbVie Reports Third-Quarter 2024 Financial Results [2024-10-30 07:38AM] 3 Dividend Growth Stocks to Buy and Never Sell [2024-10-30 07:00AM] AbbVies Deal for Alzheimers Antibody Raises Curtain for Roche News on Wednesday [Oct-29-24 05:31PM] AbbVie to Acquire Aliada Therapeutics for $1.4 Billion, Expanding Alzheimer's Pipeline [Oct-29-24 03:29PM] Navigating Market Uncertainty: Intrinsic Value of AbbVie Inc [Oct-29-24 08:00AM] SkinSpirit joins Allergan Aesthetics in Supporting Girls Inc. and Empowering the New Generation of Women in STEM [Oct-29-24 08:00AM] AbbVie's VRAYLAR® (cariprazine) Now Publicly Reimbursed in Ontario [Oct-29-24 08:00AM] AbbVie signs agreement to acquire Aliada for $1.4bn [Oct-29-24 05:33AM] AbbVie Has A New Cash Cow As Humira Bows To Skyrizi In Third-Quarter Beat [2024-10-30 11:11AM] AbbVie Stock Rises After Earnings Beat, Dividend Hike [2024-10-30 09:39AM] AbbVie (ABBV) Surpasses Q3 Earnings and Revenue Estimates [2024-10-30 08:50AM] AbbVie raises profit forecast as CEO cites business "momentum" [2024-10-30 08:07AM] AbbVie raises 2024 profit forecast on strong sales of key drugs Skyrizi, Rinvoq [2024-10-30 07:52AM] AbbVie Boosts FY24 Outlook; Boosts Dividend 5.8% - Update [2024-10-30 07:52AM] AbbVie: Q3 Earnings Snapshot [2024-10-30 07:49AM]
25-07-2024	PM		ABBV	AbbVie Inc.	305,760	2.65	2.56	2.91	AbbVie Non-GAAP EPS of $2.65 misses by $0.01, revenue of $14.46B beats by $430M [7/25/2024 7:37 AM]	182.52	6.31 (3.58%)	174.00	-2.21 (-1.25%)	135.85 - 186.11	7,483,847	4,440,000	44,042
AbbVie Non-GAAP EPS of $2.65 misses by $0.01, revenue of $14.46B beats by $430M [7/25/2024 7:37 AM] Earnings summary: AbbVie reports mixed Q2 results; raises FY24 EPS outlook [7/25/2024 7:47 AM] AbbVie in charts: Skyrizi, Rinvoq sales jump, while Humira revenue falls ~30% Y/Y in Q2 [7/25/2024 7:48 AM] AbbVie raises outlook as new immunology drugs offset Humira impact [7/25/2024 8:19 AM] Cerevel gains as AbbVie says it expects deal to close soon (update) [7/25/2024 9:44 AM]
26-04-2024	PM		ABBV	AbbVie Inc.	296,410	2.31	2.35	2.46	AbbVie Non-GAAP EPS of $2.31 beats by $0.05, revenue of $12.31B beats by $370M [4/26/2024 7:36 AM]	159.54	-7.75 (-4.63%)	166.49	-0.80 (-0.48%)	130.96 - 182.89	8,943,996	5,140,000	54,821
AbbVie Non-GAAP EPS of $2.31 beats by $0.05, revenue of $12.31B beats by $370M [4/26/2024 7:36 AM] AbbVie in charts: Q1 Skyrizi, Rinvoq sales jump, while revenue from Humira continues to fall [4/26/2024 9:10 AM] AbbVie off 3% despite quarterly beats, 2024 guidance raise [4/26/2024 10:33 AM] AbbVie Q1 report beats Street despite plunging Humira sales [4/26/2024 11:20 AM] AbbVie stock slides 6% amid concerns about falling Humira sales [4/26/2024 2:09 PM]
02-02-2024	PM		ABBV	AbbVie Inc.	290,250	2.79	2.76	3.60	AbbVie reports mixed Q4 results; raises FY24 outlook [2/2/2024 7:41 AM]	168.64	1.05 (0.63%)	168.96	1.37 (0.82%)	130.96 - 172.85	6,230,525	5,020,000	76,139
AbbVie Q4 in focus as Humira patent cliff reaches one-year mark [2/1/2024 12:10 PM] AbbVie reports mixed Q4 results; raises FY24 outlook [2/2/2024 7:41 AM] AbbVie posts Q4 revenue beat despite Humira patent cliff [2/2/2024 8:22 AM] AbbVie cites tailwinds to Botox business from weight loss drugs [2/2/2024 1:06 PM]
27-10-2023	PM		ABBV	AbbVie Inc.	258,240	2.95	2.85	3.66	AbbVie Non-GAAP EPS of $2.95 beats by $0.08, revenue of $13.93B beats by $220M [10/27/2023 7:39 AM]	138.93	-6.27 (-4.32%)	136.87	-8.33 (-5.74%)	130.96 - 168.11	7,463,257	4,700,000	100,141
AbbVie favored on Wall Street ahead of Q2 earnings [10/26/2023 12:24 PM] AbbVie raises dividend by 4.7% to $1.55 [10/27/2023 7:42 AM] AbbVie Non-GAAP EPS of $2.95 beats by $0.08, revenue of $13.93B beats by $220M [10/27/2023 7:39 AM] AbbVie stock dips despite guidance boost (update) [10/27/2023 12:08 PM] Needham says Abbvie's Botox sales results good news for Evolus, Revance [10/27/2023 3:22 PM]
27-07-2023	PM		ABBV	AbbVie Inc.	252,610	2.91	2.79	3.51	AbbVie Non-GAAP EPS of $2.91 beats by $0.10, revenue of $13.87B beats by $350M [7/27/2023 7:39 AM]	148.85	6.95 (4.90%)	144.00	2.10 (1.48%)	130.96 - 168.11	10,828,942	5,130,000	309,718
AbbVie under pressure ahead of Q2 results amid Humira cliff [7/26/2023 11:58 AM] AbbVie expands collaboration with Calibr on early-stage assets [7/26/2023 10:12 AM] AbbVie says Skyrizi beat Amgen’s Otezla in plaque psoriasis trial [7/26/2023 8:35 AM] AbbVie Non-GAAP EPS of $2.91 beats by $0.10, revenue of $13.87B beats by $350M [7/27/2023 7:39 AM] Inside AbbVie: Signs of stabilization in Humira sales? [7/27/2023 9:08 AM]
27-04-2023	PM	7:45 AM ET (Apr 27)	ABBV	AbbVie Inc.	290,910	2.46	2.44	3.16	AbbVie Non-GAAP EPS of $2.46 misses by $0.03, revenue of $12.23B in-line [4/27/2023 7:34 AM]	149.04	-12.76 (-7.89%)	155.50	-6.30 (-3.89%)	134.09 - 168.11	14,189,523	4,560,000	521,095
Democratic senators introduce bill to enhance CMS drug price negotiations [4/26/2023 1:21 PM] Will Humira competition impact AbbVie Q1 results? [4/26/2023 12:33 PM] AbbVie Non-GAAP EPS of $2.46 misses by $0.03, revenue of $12.23B in-line [4/27/2023 7:34 AM] AbbVie falls as key drugs underperform amid Humira patent cliff [4/27/2023 8:32 AM] Vertex gains as AbbVie ends cystic fibrosis development program [4/27/2023 11:09 AM]
09-02-2023	PM	7:45 AM ET (Feb 9)	ABBV	AbbVie Inc.	256,680	3.60	3.54	3.31	AbbVie Non-GAAP EPS of $3.60 beats by $0.02, revenue of $15.12B misses by $180M, initiates FY outlook [2/9/2023 7:45 AM]	148.70	4.09 (2.83%)	147.77	3.16 (2.19%)	134.09 - 175.91	10,197,853	5,300,000	307,866
AbbVie Q4 results in focus with eye on new drugs as Humira challengers enter US doors [2/8/2023 11:30 AM] AbbVie Non-GAAP EPS of $3.60 beats by $0.02, revenue of $15.12B misses by $180M, initiates FY outlook [2/9/2023 7:45 AM] AbbVie sets outlook below consensus amid generic threat to best selling drug [2/9/2023 8:22 AM] AbbVie gains after revising estimates for Humira sales erosion [2/9/2023 12:38 PM]
28-10-2022	PM	7:40 AM ET (Oct 28)	ABBV	AbbVie Inc.	269,650	3.66	3.56	3.33	AbbVie Non-GAAP EPS of $3.66 beats by $0.10, revenue of $14.81B misses by $130M, raises dividend by 5% [10/28/2022 7:45 AM]	147.50	-6.00 (-3.91%)	146.00	-7.50 (-4.89%)	108.20 - 175.91	9,191,067	4,740,000	174,215
All eyes on AbbVie Q3 results amid biosimilar competition to rheumatoid arthritis drug Humira [10/27/2022 10:20 AM] AbbVie raises dividend by 5% to $1.48 [10/28/2022 7:47 AM] AbbVie Non-GAAP EPS of $3.66 beats by $0.10, revenue of $14.81B misses by $130M, raises dividend by 5% [10/28/2022 7:45 AM] AbbVie falls as Humira international decline continues in Q3; narrows FY22 outlook [10/28/2022 8:57 AM] Genmab files for approval of blood cancer drug in US, AbbVie gets review in EU [10/28/2022 9:29 AM] AbbVie Q3 Preview: Can Shares Continue Their Run? [Oct-27-22 04:10PM] AbbVie misses sales estimates as Botox, Juvederm face slowdown jitters [Oct-28-22 07:45AM]
29-07-2022	PM	7:45 AM ET (Jul 29)	ABBV	AbbVie Inc.	262,360	3.51	3.42	3.11	AbbVie Non-GAAP EPS of $3.37 beats by $0.06, revenue of $14.58B misses by $60M, cuts FY22 EPS guidance [7/29/2022 7:43 AM]	143.65	-6.10 (-4.07%)	146.70	-3.05 (-2.04%)	105.56 - 175.91	15,064,137	5,030,000	31,351
AbbVie asks FDA, EMA to approve Rinvoq for Crohn's disease [7/28/2022 11:58 AM] All eyes on AbbVie Q2 results amid challenges to rheumatoid arthritis drug Humira [7/28/2022 11:38 AM] AbbVie Rinvoq wins another approval in EU for spinal arthritis subtype [7/29/2022 6:28 AM] AbbVie Non-GAAP EPS of $3.37 beats by $0.06, revenue of $14.58B misses by $60M, cuts FY22 EPS guidance [7/29/2022 7:43 AM] AbbVie stock dips while Q2 revenue soars on back of blockbuster Humira; sets aside ~$2B for opioid claims [7/29/2022 9:03 AM] Dow Jones Futures Rise: Market Rally Extends Momentum As Apple Pops, Amazon Soars On Earnings [Jul-29-22 07:36AM] RINVOQ® (upadacitinib) Approved by European Commission as an Oral Treatment for Adults with Active Non-Radiographic Axial Spondyloarthritis [Jul-29-22 02:00AM] 5 NYSE Stocks To Watch And Buy: Here Are Fundamental And Technical Reasons Why [Jul-28-22 01:48PM] 10 High-Yield But Safe Dividend Stocks to Buy Now [Jul-28-22 09:37AM] Pfizer (PFE) Q2 Earnings and Revenues Surpass Estimates [Jul-28-22 08:05AM] Allergan To End Around 3,000 Opioid Lawsuits With Over $2B In Settlement: Report [Jul-28-22 07:42AM]
29-04-2022	PM	7:45 AM ET (Apr 29)	ABBV	AbbVie Inc.	278,400	3.16	3.15	2.95	AbbVie Non-GAAP EPS of $3.16 beats by $0.02, revenue of $13.54B misses by $70M [4/29/2022 7:44 AM]	146.85	-9.46 (-6.05%)	148.93	-7.38 (-4.72%)	105.56 - 175.91	20,338,728	7,630,000	209,424
All eyes on AbbVie Q1 results amid challenges to Humira's dominance [4/28/2022 12:13 PM] Abbvie, Plexium team up to develop therapies for neurological disorders [4/28/2022 9:11 AM] AbbVie Non-GAAP EPS of $3.16 beats by $0.02, revenue of $13.54B misses by $70M [4/29/2022 7:44 AM] AbbVie down 8% after lowering full-year guidance, quarterly revenue miss (updated) [4/29/2022 8:42 AM] AbbVie announces FDA approval of Rinvoq for new arthritic indication [4/29/2022 3:09 PM] Dow Jones Futures Fall After Facebook-Led Market Rally; Apple Earnings Top, Amazon Tumbles [Apr-28-22 06:11PM] Drug/Biotech Stocks Q1 Earnings Due on Apr 29: BMY, ABBV, AZN [Apr-28-22 10:53AM] Why Earnings Season Could Be Great for AbbVie (ABBV) [Apr-28-22 09:35AM] Allergan, an AbbVie Company, to Present New Data from its Leading Portfolio of Eye Care Treatments at the 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting [Apr-28-22 08:30AM] Abbvie and Plexium Enter Into Multi-Target Strategic Collaboration To Develop and Commercialize Targeted Protein Degradation Therapies for Neurological Conditions [Apr-28-22 08:00AM] Eli Lilly (LLY) Q1 Earnings and Revenues Top Estimates [Apr-28-22 07:35AM] AbbVie misses quarterly sales estimates as Humira rivals bite [Apr-29-22 07:48AM] AbbVie Reports First-Quarter 2022 Financial Results [Apr-29-22 07:43AM] AbbVie's stock is down 3% after missing on revenue in the first quarter of 2022 [Apr-29-22 08:07AM] AbbVie Crumbles On Mixed Earnings, Slashes 2022 Profit Outlook [Apr-29-22 08:37AM] AbbVie misses quarterly sales expectations on Humira competition [Apr-29-22 07:48AM] AbbVie Shares Drop Amid Missed Sales Expectations for Key Drugs [Apr-29-22 10:02AM] AbbVie misses sales estimates on Humira weakness, shares fall [Apr-29-22 07:48AM] Stock Market Drops On Lackluster Earnings From Amazon, Apple [Apr-29-22 10:43AM] AbbVie (ABBV) Tops Q1 Earnings Estimates [Apr-29-22 09:05AM] Stock Market Volatile; Apple, Facebook, Amazon Are Key Earnings, Tesla CEO Elon Musk Buys Twitter: Weekly Review [Apr-29-22 11:59AM] AbbVie Plunges on Revenue Miss - Imbruvica and Humira Revenue Decline [Apr-29-22 06:10AM] AbbVie Shares Fall On Mixed Bag Q1 Results, Cuts FY22 Profit Guidance [Apr-29-22 09:40AM] AbbVie (ABBV) Q1 Earnings Top, Competition Rises for Imbruvica [Apr-29-22 11:20AM] Stock Market Down More Than 2%, Wiping Out Most Of Thursday's Rally; Amazon Hits Indexes [Apr-29-22 01:46PM] RINVOQ® (upadacitinib) Approved by U.S. FDA as an Oral Treatment for Adults with Active Ankylosing Spondylitis [Apr-29-22 02:44PM] Why AbbVie's Shares Dropped 10.5% Friday [Apr-29-22 04:46PM] 10 Stocks Tumbling Today [Apr-29-22 03:54PM]
02-02-2022	PM	7:40 AM ET (Feb 2)	ABBV	AbbVie Inc.	243,830	3.31	3.28	2.92	AbbVie Non-GAAP EPS of $3.31 beats by $0.03, revenue of $14.89B misses by $70M [2/2/2022 7:45 AM]	138.81	1.81 (1.32%)	136.34	-0.66 (-0.48%)	102.05 - 139.41	9,440,816	8,710,000	288,029
Gilead’s COVID-19 therapy beats AbbVie’s Humira to lead U.S. hospital spending in 2021 [2/1/2022 3:46 PM] Will AbbVie's upbeat earnings pattern continue in Q4? [2/1/2022 7:38 AM] AbbVie Non-GAAP EPS of $3.31 beats by $0.03, revenue of $14.89B misses by $70M [2/2/2022 7:45 AM] AbbVie beats Q4 non-GAAP EPS forecast; 2022 guidance tops consensus [2/2/2022 8:32 AM] Verity & Verity, LLC Buys LyondellBasell Industries NV, Verizon Communications Inc, ... [Feb-01-22 05:38PM] Leonard Rickey Investment Advisors P.L.L.C. ... [Feb-01-22 01:38PM] Is AbbVie Stock a Buy Now? [Feb-01-22 11:45AM] Pharma Stocks to Report Q4 Earnings on Feb 2: ABBV, NVS & NVO [Feb-01-22 09:45AM] James Hambro & Partners Buys Netflix Inc, Pool Corp, Union Pacific Corp, Sells Comcast ... [Feb-01-22 09:38AM] AbbVie Showcases Its Leadership in Research in Inflammatory Bowel Diseases with New Analyses to be Presented at the 17th Congress of European Crohn's and Colitis Organization (ECCO) [Feb-01-22 08:45AM] Why AbbVie (ABBV) Might Surprise This Earnings Season [Feb-01-22 08:30AM] 3 Warren Buffett Dividend Stocks to Buy in February [Feb-01-22 05:56AM] 3 Pharmaceutical Stocks With Dividend Yields of 2.9% or Better [Feb-01-22 05:39AM] AbbVie's Charts Look Strong Ahead of Earnings [Feb-01-22 05:22AM] 5 High-Yield Dividend Stocks That Can Save Your Portfolio During a Stock Market Crash [Feb-01-22 05:06AM] Axel Capital Management, LLC Buys Silvergate Capital Corp, Riot Blockchain Inc, Meta Platforms ... [Feb-01-22 09:38PM] Were Hedge Funds Right About AbbVie Inc (ABBV)? [Feb-02-22 01:17AM] Greystone Financial Group, LLC Buys iShares U.S. ... [Feb-01-22 09:38PM] AbbVie Reports Full-Year and Fourth-Quarter 2021 Financial Results [Feb-02-22 07:43AM] AbbVie's stock gains on fourth-quarter earnings as it reports better-than-expected sales of Humana [Feb-02-22 08:06AM] AbbVie's stock gains on fourth-quarter earnings as it reports better-than-expected sales of Humira [Feb-02-22 08:21AM] AbbVie Earnings Slightly Beat Estimates. Here Are the Numbers That Matter. [Feb-02-22 09:17AM] AbbVie Earnings Come In Mixed, Though Guidance Offers A Hefty Beat [Feb-02-22 09:32AM] Argent Advisors, Inc. Buys iShares 10-20 Year Treasury Bond ETF, Pinnacle West Capital Corp, ... [Feb-02-22 09:38AM] Demars Financial Group, LLC Buys iShares TIPS Bond ETF, Medical Properties Trust Inc, Phillips ... [Feb-02-22 09:38AM] Meridian Wealth Advisors, LLC Buys Vanguard S&P 500 ETF, Vanguard Mid-Cap ETF, JPMorgan ... [Feb-02-22 09:38AM] AbbVie (ABBV) Tops Q4 Earnings Estimates [Feb-02-22 09:05AM] AbbVie Sales Lag As Humira Competition Heats Up And U.S. Biosimilars Loom [Feb-02-22 12:13PM] AbbVie's (ABBV) Q4 Earnings Surpass Estimates, Sales Miss [Feb-02-22 11:40AM] MV Capital Management, Inc. Buys Abbott Laboratories, AbbVie Inc, Fidelity Blue Chip Growth ... [Feb-02-22 01:38PM] Truepoint, Inc. Buys Avantis Emerging Markets Equity ETF, Vanguard Intermediate-Term Corporate ... [Feb-02-22 01:38PM] UPDATE 1-U.S. FDA approves first generic form of AbbVie's eye drug [Feb-02-22 01:52PM] UPDATE 2-U.S. FDA approves first generic version of AbbVie's dry-eye drug [Feb-02-22 01:52PM] Chase Investment Counsel Corp Buys Eagle Materials Inc, National Fuel Gas Co, AbbVie Inc, Sells ... [Feb-02-22 05:38PM]
29-10-2021	PM	7:45 AM ET (Oct 29)	ABBV	AbbVie Inc.	193,490	3.33	3.23	2.83	AbbVie EPS beats by $0.11, beats on revenue, raises guidance [10/29/2021 7:43 AM]	114.53	4.86 (4.43%)	111.96	2.29 (2.09%)	79.11 - 121.53	13,233,217	5,310,000	241,915
AbbVie EPS beats by $0.11, beats on revenue, raises guidance [10/29/2021 7:43 AM] AbbVie hikes dividend by ~9% to $1.41 per share, stock yields 5.2% [10/29/2021 7:47 AM] AbbVie's cariprazine meets main goal in late-stage major depressive disorder study [10/29/2021 8:03 AM] AbbVie sets better-than-expected 2021 guidance despite slowdown in topline growth [10/29/2021 8:17 AM] FDA approves AbbVie's Vuity eye drops for age-related farsightedness [10/29/2021 1:53 PM] What Investors Should Pay Attention to in AbbVie's Q3 Earnings Report [Oct-28-21 12:46PM] Should Investors Worry About AbbVie? [Oct-28-21 10:30AM] AbbVie Announces ABBV-951 (Foslevodopa/Foscarbidopa) Showed Improvement in Controlling Motor Fluctuations Compared to Oral Levodopa/Carbidopa Medication in Pivotal Phase 3 Trial in Patients with Advanced Parkinson's Disease [Oct-28-21 08:15AM] AbbVie gets a shot in the arm from newer drug sales, lifts profit view [Oct-29-21 07:43AM] AbbVie Reports Third-Quarter 2021 Financial Results [Oct-29-21 07:40AM] AbbVie's Cariprazine (VRAYLAR®) Met Primary Endpoint in Phase 3 Study as an Adjunctive Treatment for Major Depressive Disorder [Oct-29-21 07:50AM] AbbVie Stock Rises on Earnings Beat and Guidance Boost [Oct-29-21 07:54AM] UPDATE 1-AbbVie gets a shot in the arm from newer drug sales, lifts profit view [Oct-29-21 08:09AM] Premarket Movers Friday - Amazon, AbbVie, Apple [Oct-29-21 04:49AM] AbbVie Stock Nears Breakout After Topping Forecasts As Botox Sales Rocket [Oct-29-21 08:57AM] AbbVie Stock Rises on Stronger-Than-Expected Q3, Lifted Guidance [Oct-29-21 05:57AM] Drug maker AbbVie reports 'excellent' third quarter [Oct-29-21 10:28AM] AbbVie (ABBV) Tops Q3 Earnings Estimates [Oct-29-21 09:05AM] UPDATE 2-AbbVie confident of blockbuster drug replacements, lifts profit view third time [Oct-29-21 08:09AM] AbbVie confident of blockbuster drug replacements, lifts profit view third time [Oct-29-21 07:43AM] AbbVie Stock Gains After Hiking FY21 Earnings Outlook, Annual Dividend [Oct-29-21 08:04AM] AbbVie Performs Third-Quarter Hat Trick Here's What You Need To Know [Oct-29-21 11:22AM] Pharma Stock Roundup: Big Pharma Q3 Results, FDA Panel's Vote for PFE COVID Jab [Oct-29-21 10:41AM] AbbVie's Major Depressive Disorder Candidate Shows Mixed Result In Late-Stage Trials [Oct-29-21 09:18AM] AbbVie's (ABBV) Q3 Earnings Beat, 2021 EPS Guidance Raised [Oct-29-21 11:06AM] 5 Top Gainers for Friday: U.S. Steel, Lululemon, VeriSign [Oct-29-21 09:24AM] AbbVie Stock Retakes Its 50-Day Line On Bullish Earnings Is It A Buy Right Now? [Oct-29-21 01:43PM] Abbvie Jumps After Raising Dividend, Annual Profit Forecast [Oct-29-21 09:33AM] Why Are CareDx Shares Slumping Despite Q3 Earnings Beat? [Oct-29-21 12:03PM] AbbVie (ABBV) Q3 2021 Earnings Call Transcript [Oct-29-21 03:31PM] U.S. Food and Drug Administration Approves VUITY (pilocarpine HCI ophthalmic solution) 1.25%, the First and Only Eye Drop to Treat Presbyopia (Age-Related Blurry Near Vision) [Oct-29-21 05:31PM] Why AbbVie Shares Are Rising Today [Oct-29-21 12:44PM]
30-07-2021	PM	7:40 AM ET (Jul 30)	ABBV	AbbVie Inc.	209,390	3.11	3.11	2.34	AbbVie EPS beats by $0.08, beats on revenue, raises FY21 Non-GAAP guidance [7/30/2021 7:45 AM]	116.24	-2.63 (-2.21%)	119.00	0.13 (0.11%)	79.11 - 119.15	7,001,281	5,180,000	37,987
AbbVie Q2 2021 Earnings Preview [7/29/2021 3:25 PM] AbbVie EPS beats by $0.08, beats on revenue, raises FY21 Non-GAAP guidance [7/30/2021 7:45 AM] AbbVie tops Q2 forecast; non-GAAP EPS outlook for FY21 raised [7/30/2021 8:15 AM] AbbVie to advance beta-amyloid Alzheimer's candidate, abandons tau asset [7/30/2021 11:51 AM] FTC drops antitrust complaint against AbbVie after Supreme Court declines case review [7/30/2021 2:35 PM] Should You Buy AbbVie (ABBV) Ahead of Earnings? [Jul-29-21 11:09AM] How AbbVie Could Make an Entry Into This Rapidly Growing Drug Market [Jul-29-21 10:35AM] Match Group (MTCH) to Post Q2 Earnings: Is a Beat in Store? [Jul-29-21 09:07AM] Market Crash 2.0: Where to Invest $1,000 [Jul-29-21 08:31AM] FDA Approves Expanded BOTOX® (onabotulinumtoxinA) Label to Include Eight New Muscles to Treat Adults with Upper Limb Spasticity [Jul-29-21 08:30AM] Before AbbVie's Inc. (NYSE:ABBV) Earnings Call Tomorrow, Consider their Debt [Jul-29-21 02:22AM] AbbVie raises annual profit forecast as Botox demand rebounds [Jul-30-21 07:49AM] AbbVie raises annual profit forecast as Botox demand rebounds [Jul-30-21 07:46AM] AbbVie Reports Second-Quarter 2021 Financial Results [Jul-30-21 07:44AM] AbbVie Earnings Edge Past Views With Stock Right At Buy Point [Jul-30-21 07:58AM] AbbVie cites growth of immunology business in the second quarter [Jul-30-21 08:17AM] Amazon, Pinterest Fall Premarket; Chevron, P&G Rise [Jul-30-21 04:01AM] UPDATE 1-AbbVie raises annual profit forecast as Botox demand rebounds [Jul-30-21 08:57AM] AbbVie Boosts Full-Year Guidance as Sales Rebound From Pandemic [Jul-30-21 07:49AM] AbbVie Boosts 2021 Guidance as Sales Rebound From Pandemic [Jul-30-21 09:35AM] Zacks Earnings ESP: A Better Way to Find Earnings Surprises for Medical [Jul-30-21 08:50AM] Have $500? Here Are 2 High-Yielding Healthcare Stocks to Consider [Jul-30-21 10:14AM] AbbVie (ABBV) Q2 Earnings Match Estimates [Jul-30-21 09:05AM] UPDATE 2-AbbVie expects Botox boom to power annual earnings [Jul-30-21 08:57AM] AbbVie expects Botox boom to power annual earnings [Jul-30-21 07:49AM] AbbVie Q2 Earnings Beats Consensus Slightly; Guides FY21 EPS Below Consensus [Jul-30-21 08:19AM] Pharma Stock Roundup: Q2 Earnings of MRK, PFE & Others, FDA Approvals for GSK, ABBV [Jul-30-21 10:12AM] AbbVie's (ABBV) Q2 Earnings In Line, 2021 Guidance Raised [Jul-30-21 11:40AM]
30-04-2021	PM	7:40 AM ET (Apr 30)	ABBV	AbbVie Inc.	196,670	2.95	2.77	2.42	AbbVie EPS beats by $0.12, beats on revenue [4/30/2021 7:43 AM]	111.46	0.57 (0.51%)	111.51	0.62 (0.56%)	79.11 - 113.41	7,122,910	5,460,000	101,920
AbbVie Q1 2021 Earnings Preview [4/29/2021 12:35 PM] AbbVie EPS beats by $0.12, beats on revenue [4/30/2021 7:43 AM] AbbVie posts Q1 earnings beat, raises FY profit forecast [4/30/2021 8:02 AM] Abbvie CEO Richard Gonzalez to testify before House committee in drug pricing probe [4/30/2021 10:52 AM] AstraZeneca, Merck, AbbVie Struck Biggest Licensing Deals in 2020 [Apr-29-21 05:21PM] Bristol-Myers Misses Q1 Profit As Pandemic Hits Cancer Drugs Sales [Apr-29-21 10:49AM] 2 Undervalued Pharmaceutical Stocks to Buy Now [Apr-29-21 06:15AM] AbbVie Reports First-Quarter 2021 Financial Results [Apr-30-21 07:42AM] Abbvie Posts First-Quarter Earnings Beat and Raises Guidance [Apr-30-21 04:03AM] AbbVie's stock is up 2.0% as Humira sales top $3.9 billion in sales in the first quarter [Apr-30-21 08:18AM] 3 Warren Buffett Stocks Worth Buying Now [Apr-30-21 08:17AM] AbbVie's stock is up 2.0% as Humira sales top $4.8 billion in sales in the first quarter [Apr-30-21 08:45AM] AbbVie Stock Pops On Earnings Beat; Raises 2021 Profit Outlook [Apr-30-21 08:41AM] AbbVie Posts First-Quarter Earnings Beat and Raises Guidance [Apr-30-21 04:03AM] AbbVie (ABBV) Surpasses Q1 Earnings and Revenue Estimates [Apr-30-21 09:05AM] How AbbVie Beat Expectations Again in Q1 [Apr-30-21 10:35AM] AbbVie Stock Dips Away From Breakout Despite First-Quarter Beat And Raise [Apr-30-21 10:46AM] UPDATE 2-AbbVie expects Botox sales recovery in Europe after U.S. rebound [Apr-30-21 09:06AM] AbbVie expects Botox sales recovery in Europe after U.S. rebound [Apr-30-21 07:51AM] AbbVie (ABBV) Beats on Q1 Earnings, Raises 2021 Guidance [Apr-30-21 11:07AM] AbbVie Beats Q1 Earnings On Strong Humira Sales, Raises Full-Year Profit Forecast [Apr-30-21 09:17AM] Here's Why Shareholders May Want To Be Cautious With Increasing AbbVie Inc.'s (NYSE:ABBV) CEO Pay Packet [Apr-30-21 08:32AM] AbbVie (ABBV) Q1 2021 Earnings Call Transcript [Apr-30-21 03:31PM] AbbVie Rises on Q1 Beats, Raised EPS Guidance [Apr-30-21 04:27PM] AbbVie Stock Nears Breakout After First-Quarter Beat And Raise [Apr-30-21 04:26PM]
03-02-2021	PM	7:45 AM ET (Feb 3)	ABBV	AbbVie Inc.	180,610	2.92	2.85	2.21	AbbVie EPS beats by $0.07, beats on revenue [2/3/2021 7:39 AM]	107.53	2.53 (3.92%)	106.00	2.53 (2.45%)	62.55 - 113.41	10,122,068	7,744,182	202,692
AbbVie EPS beats by $0.07, beats on revenue [2/3/2021 7:39 AM] AbbVie Q4 2020 Earnings Preview [2/2/2021 12:59 PM] AbbVie tops Q4 forecast, guides 2021 non-GAAP EPS above consensus [2/3/2021 9:06 AM] Here's Why Investors Liked AbbVie's Q4 Results [Feb-03-21 12:00PM] AbbVie Lands In Buy Zone On Earnings Beat, Strong 2021 Guidance [Feb-03-21 11:38AM] AbbVies 4Q Profit Tops Analysts Estimates; Shares Gain [Feb-03-21 11:13AM] AbbVie (ABBV) Q4 Earnings & Sales Top, 2021 Outlook Bright [Feb-03-21 10:46AM] Unusual Options Activity Insight: AbbVie [Feb-03-21 09:46AM] With Clock Ticking on Humira, AbbVie Plans for 2021 Growth [Feb-03-21 09:39AM] AbbVie: Q4 Earnings Insights [Feb-03-21 07:54AM] The Daily Biotech Pulse: Amgen Earnings, GSK-CureVac Vaccine Collaboration, Mallinckrodt FDA Decision [Feb-03-21 07:31AM] AbbVie Beats Earnings Expectations as Sales Surge [Feb-03-21 03:55AM]
30-10-2020	PM	7:45 AM ET (Oct 30)	ABBV	AbbVie Inc.	148,850	2.83	2.75	2.33	AbbVie EPS beats by $0.06, beats on revenue [10/30/2020 7:49 AM]	85.13	4.46 (5.53%)	83.60	2.93 (3.63%)	62.55 - 101.28	13,851,210	7,972,976	209,880

31-07-2020	PM	7:45 AM ET (Jul 31)	ABBV	AbbVie Inc.	170,970	2.34	2.24	2.26	AbbVie EPS beats by $0.14, beats on revenue [7/31/2020 7:46 AM]	94.06	-1.98 (-2.06%)	96.29	0.25 (0.26%)	62.55 - 101.28	4,962,822	5,759,455	122,320